Roche-Spark deal faces FTC Republicans who overruled Democrats on BMS-Celgene
Washington, D.C. ( December 17, 2019) -- Roche’s acquisition of Spark Therapeutics is pending before a Federal Trade Commission that was starkly divided along party lines in a recent pharma deal that the Republican majority was willing to allow....